SANTA MONICA, Calif.– GoodRx has announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of GoodRx for Weight Loss, a telemedicine subscription that connects consumers to licensed healthcare providers for affordable weight management treatment. Second, in partnership with Novo Nordisk, a new introductory cash price of $199 per month for Ozempic (semaglutide) and Wegovy (semaglutide) injection pens, available to GoodRx users.
“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards. By uniting nationwide pharmacy integration, home delivery capabilities, and transparent pricing in one seamless experience, GoodRx is creating a higher standard for affordability and trust in weight loss care.”
GoodRx for Weight Loss is a comprehensive, direct-to-consumer telemedicine subscription built to simplify every step of the GLP-1 treatment journey, from consultation to prescription to fulfillment.
GoodRx for Weight Loss features include:
- GoodRx savings on brand medications, including the lowest cash prices available for any FDA-approved GLP-1 medications for weight loss treatment.
- Transparent pricing so consumers know what they’ll pay upfront, with no hidden fees.
- Flexible fulfillment options, including in-store pick-up at nearly all retail pharmacy locations nationwide for Wegovy or Zepbound® (tirzepatide) pens, or convenient home delivery for the Zepbound vial formulation via LillyDirect.
- Virtual consultations with licensed healthcare providers to determine eligibility and if appropriate, write a prescription for FDA-approved GLP-1 treatments for weight loss.
- Ongoing clinical support to track progress, manage side effects, and adjust treatment as needed.
- A personalized, consumer-first experience that prioritizes safety, affordability, and convenience.
The GoodRx for Weight Loss telemedicine subscription is available for an introductory rate of $39 per month through January 2026, with a standard price of $119 beginning on February 1, 2026. Medications are priced separately, allowing customers to only pay for what they need.
Delivering Real Savings on the Most Trusted GLP-1 Medications
Building on its collaboration with Novo Nordisk, GoodRx is now offering savings on Ozempic and Wegovy injection pens to first-time GoodRx users for an introductory price of $199 per month for the first two fills of the two lowest doses (0.25 mg and 0.5 mg), followed by an ongoing price of $349 per month for subsequent fills.* This new reduced pricing makes two of the most in-demand GLP-1 treatments more affordable and accessible for eligible self-paying patients at nearly all pharmacies nationwide.
Whether a consumer already has a prescription or needs help getting started, GoodRx provides a simple, straightforward path to treatment:
- Already have a prescription? Search for Ozempic or Wegovy on GoodRx to unlock industry-leading prices as low as $199 per month for the first two fills.
- Need a prescription? Sign up for GoodRx for Weight Loss to connect with a licensed healthcare provider who can evaluate your needs and, if appropriate, prescribe safe and effective GLP-1 treatment that meets proven standards.
Together, these initiatives reinforce GoodRx’s leadership in making trusted, science-backed GLP-1 treatments more affordable and easier to obtain. As the nation’s leading platform for prescription savings, GoodRx is redefining what consumer-first healthcare looks like, delivering safe, affordable, and scalable solutions that help more people start and stay on effective treatment.
